Eurofins Scientific
ERFFrance
8 filed reports · 9 financial concepts · 15 earnings calls · 0 media appearances
Filed reports
8 reports · Mar 2021 to Mar 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Q1AMF | 6 | 37 | Mar 2021 to Mar 2026 |
| Q3AMF | 2 | 24 | Sep 2022 to Sep 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q1 | q1 | Mar 31, 2026 | Apr 22, 2026 | 8 | Open |
| FY2025 Q3 | q3 | Sep 30, 2025 | Oct 21, 2025 | 18 | Open |
| FY2025 Q1 | q1 | Mar 31, 2025 | Apr 23, 2025 | 11 | Open |
| FY2024 Q1 | q1 | Mar 31, 2024 | Apr 24, 2024 | 6 | Open |
| FY2023 Q1 | q1 | Mar 31, 2023 | Apr 26, 2023 | 3 | Open |
| FY2022 Q3 | q3 | Sep 30, 2022 | Oct 18, 2022 | 6 | Open |
| FY2022 Q1 | q1 | Mar 31, 2022 | Apr 21, 2022 | 5 | Open |
| FY2021 Q1 | q1 | Mar 31, 2021 | Apr 28, 2021 | 4 | Open |
Financial data
9 concepts · 61 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Segment1 concepts · 46 facts · Mar 2021 to Mar 2026
- Revenue46 · Mar 2021 to Mar 2026
KPI5 concepts · 7 facts · Mar 2024 to Sep 2025
- blood collection points2 · Mar 2024 to Mar 2025
- new start-up laboratories2 · Mar 2024 to Mar 2025
- Blood collection points opened1 · Sep 2025
- Business combinations1 · Mar 2025
- Total1 · Sep 2025
IFRS1 concepts · 6 facts · Mar 2021 to Mar 2026
- Revenue6 · Mar 2021 to Mar 2026
APM2 concepts · 2 facts · Mar 2022
- Q1 2022 organic growth rate (b/a-1)1 · Mar 2022
- Q1 2022 organic scope* revenues (at Q1 2022 FX rates) (b)1 · Mar 2022
Segments
46 factsFigures broken down by business line, region, product or another axis the company reports on.
Operating segment: europe1 member · 10 facts
- Europe10 · Mar 2021 to Mar 2026
Operating segment: north america1 member · 10 facts
- North America10 · Mar 2021 to Mar 2026
Operating segment: rest of the world1 member · 10 facts
- Rest of the World10 · Mar 2021 to Mar 2026
Area of activity: bio pharma1 member · 4 facts
- BioPharma4 · Mar 2025 to Mar 2026
Area of activity: consumer & technology products testing1 member · 4 facts
- Consumer & Technology Products Testing4 · Mar 2025 to Mar 2026
Area of activity: diagnostic services & products1 member · 4 facts
- Diagnostic Services & Products4 · Mar 2025 to Mar 2026
Area of activity: life1 member · 4 facts
- Life4 · Mar 2025 to Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
15 calls · Aug 2019 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 23, 2026
- FY2026 Q1Apr 22, 2026
- FY2025 Q4Jan 29, 2026
- FY2025 Q3Oct 21, 2025
- FY2025 Q2Jul 23, 2025
- FY2025 Q1Apr 23, 2025
- FY2024 Q4Jan 30, 2025
- FY2024 Q3Oct 22, 2024
- FY2024 Q2Jul 24, 2024
- FY2024 Q1Apr 24, 2024
- FY2023 Q4Feb 27, 2024
- FY2023 Q3Oct 24, 2023
- FY2023 Q1Apr 26, 2023
- FY2022 Q4Mar 3, 2023
- FY2019 Q2Aug 29, 2019
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.